menu
    • menu
    [{"orgOrder":0,"company":"ActualEyes","sponsor":"Arctic Vision","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Rho-Associated Kinase-Human Corneal Endothelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ActualEyes","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"ActualEyes \/ Arctic Vision","highestDevelopmentStatusID":"4","companyTruncated":"ActualEyes \/ Arctic Vision"},{"orgOrder":0,"company":"SanBio","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"Vandefitemcel","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SanBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"SanBio \/ OcuMension Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SanBio \/ OcuMension Therapeutics"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellusion

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Cellusion

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLS001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Hangzhou Celregen Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corne...

                            Details : Under the Agreement, Celregen will have the exclusive right to develop, manufacture and commercialize CLS001 for bullous keratopathy in the Greater China region, including Mainland China, Hong Kong, Macau and Taiwan.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 12, 2022

                            Lead Product(s) : CLS001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Hangzhou Celregen Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ActualEyes

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ActualEyes

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rho-Associated Kinase-Human Corneal Endothelial Cell

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Arctic Vision

                            Deal Size : $35.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Arctic Vision Announces Exclusive Licensing Agreement With ActualEyes to Develop and Commercialize Cell Therap...

                            Details : Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhi...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 14, 2021

                            Lead Product(s) : Rho-Associated Kinase-Human Corneal Endothelial Cell

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Arctic Vision

                            Deal Size : $35.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SanBio

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SanBio

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vandefitemcel

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : OcuMension Therapeutics

                            Deal Size : $71.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sanbio and Ocumension Ink Pact For Research, Development of Innovative Stem Cell Therapies for Ophthalmic Dise...

                            Details : Ocumension obtains exclusive rights from SanBio to develop and commercialize SB623 and MSC2 in Greater China for ophthalmic indications.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $6.0 million

                            March 31, 2020

                            Lead Product(s) : Vandefitemcel

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : OcuMension Therapeutics

                            Deal Size : $71.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth